Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00148759
Status:
COMPLETED
Last Update Posted:
2013-12-03
First Post:
2005-09-06
Brief Title:
Kaletra SexGender Pharmacokinetics PK Study
Sponsor:
Emory University
Organization:
Emory University
Study Overview
Official Title:
A Switch From Twice Daily to Once Daily LopinavirRitonavir A 24-hour Pharmacokinetic Profile to Evaluate Sex Differences
Status:
COMPLETED
Status Verified Date:
2013-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
LPVGenderPK
Brief Summary:
The levels of lopinavir achieved in the blood following oral ingestion of standard doses of Kaletra lopinavirritonavir in HIV-infected men was compared with those achieved in HIV-infected women receiving the same dose of the drug
Detailed Description:
The association between patient sex and the tolerability of antiretroviral drugs ARVs is increasingly being recognized Several lines of evidence suggest that women are more likely than men to develop side effects to ARVs On the other hand it has been generally accepted that the efficacies of the ARVs are similar in both sexes However recent studies suggest that this may not always be the case In addition to these observed sex-related differences in the effects of ARVs there is growing evidence that the pharmacokinetic profile of some of these drugs may be different among male and female HIV infected patients
The fact that female sex is a risk factor for enhanced antiretroviral effects including toxicities has an important implication particularly from a global health perspective as women now represent the fastest growing segment of the HIVAIDS epidemic Therefore an understanding of the magnitude clinical significance and the mechanisms underlying this phenomenon deserves further study Knowledge acquired from such studies will likely contribute to improved survival among female HIV-infected patients through optimization of antiretroviral therapeutic regimens in manners that minimize serious adverse effects and improve adherence
Similarly the influence of race on the pharmacological effects of ARVs deserves further investigation Although there is no reason to believe based on available evidence that racial differences exist in the pharmacological effects of ARVs the need however exists to explore the influence of race on ARVs pharmacokinetics and treatment outcomes This is so because data on race related differences on ARV effects is limited and in addition people of ethnic minority have been disproportionately under represented in clinical trials involving these drugs in spite of the fact that they bear a larger burden of the HIV epidemic
Our study will examine the influence of race and sex on the 24-hr pharmacokinetics of lopinavirritonavir an antiretroviral agent commonly used in naïve patients following a switch from LPVr 400100 mg twice daily to 800200 mg once daily dosing Tolerability measured by toxicity grade of diarrhea and change in quality of life following switch from twice daily to once daily dosing will also be assessed using appropriate validated measurement tools
The fact that female sex is a risk factor for enhanced antiretroviral effects including toxicities has an important implication particularly from a global health perspective as women now represent the fastest growing segment of the HIVAIDS epidemic Therefore an understanding of the magnitude clinical significance and the mechanisms underlying this phenomenon deserves further study Knowledge acquired from such studies will likely contribute to improved survival among female HIV-infected patients through optimization of antiretroviral therapeutic regimens in manners that minimize serious adverse effects and improve adherence
Similarly the influence of race on the pharmacological effects of ARVs deserves further investigation Although there is no reason to believe based on available evidence that racial differences exist in the pharmacological effects of ARVs the need however exists to explore the influence of race on ARVs pharmacokinetics and treatment outcomes This is so because data on race related differences on ARV effects is limited and in addition people of ethnic minority have been disproportionately under represented in clinical trials involving these drugs in spite of the fact that they bear a larger burden of the HIV epidemic
Our study will examine the influence of race and sex on the 24-hr pharmacokinetics of lopinavirritonavir an antiretroviral agent commonly used in naïve patients following a switch from LPVr 400100 mg twice daily to 800200 mg once daily dosing Tolerability measured by toxicity grade of diarrhea and change in quality of life following switch from twice daily to once daily dosing will also be assessed using appropriate validated measurement tools
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| GCRC0605G | OTHER | Other | None |
| UPN 04092824 | OTHER_GRANT | None | None |